Anthem Biosciences Boosts Neoanthem's Equity with ₹275 Cr Loan Conversion

Anthem Biosciences announced the execution of the First Amendment to its loan agreement, enabling an additional conversion of up to ₹275 crore into equity shares of its wholly owned subsidiary, Neoanthem Lifesciences Private Limited. This conversion is part of the overall sanctioned financial assistance limit of ₹550 crore.

Reader Takeaway: Subsidiary equity bolstered; future conversion approvals critical.

What just happened (today’s filing)

Anthem Biosciences, a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO), has amended its loan agreement with its wholly owned subsidiary, Neoanthem Lifesciences Private Limited. The amendment, executed on February 23, 2026, allows for an additional ₹275 crore of the outstanding loan to be converted into equity shares.

This move is part of a larger sanctioned financial assistance limit of ₹550 crore, of which ₹100 crore was already converted into equity in February 2025. The outstanding loan amount, as of the disclosure date, stood at ₹439.41 Crores.

The company affirmed that the transaction is conducted on an arm's length basis and is not expected to materially impact Anthem Biosciences' consolidated financial statements.

Why this matters

This financial restructuring signifies Anthem Biosciences' commitment to strengthening its subsidiary's capital base through equity infusion. Converting debt into equity for Neoanthem will reduce the parent company's loan exposure to its subsidiary while increasing its equity investment.

For Anthem Biosciences, this is a strategic financial manoeuvre, potentially aimed at optimizing the capital structure of its subsidiary as the company continues to grow its integrated CRDMO services globally.

The backstory (grounded)

Anthem Biosciences, a prominent player in the biosciences sector, was founded in 2007 and is headquartered in Bengaluru. The company operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), offering end-to-end services across drug discovery, development, and manufacturing. It successfully converted from a private to a public company in December 2024 and completed its Initial Public Offering (IPO) around July 2025. This recent public listing suggests a strategic focus on capital optimisation and funding its expansion plans.

What changes now

• Neoanthem Lifesciences will receive additional equity funding from its parent, Anthem Biosciences.
• Anthem Biosciences's balance sheet will reflect a reduced loan asset and a higher equity investment in its subsidiary.
• The overall debt exposure of Anthem Biosciences to Neoanthem will decrease upon conversion.
• The subsidiary's equity structure will be strengthened, potentially improving its financial flexibility.

Risks to watch

• Insider Trading Violations: In November 2025, Anthem Biosciences disclosed violations of its insider trading code by two designated employees. One employee sold shares during a trading window closure, and another sold shares without prior approval. Both received warning letters from the Audit Committee, highlighting ongoing governance vigilance.
• Conversion Approvals: The additional conversion of ₹275 crore is subject to applicable approvals being obtained at the time of actual conversion, introducing an element of future procedural dependency.

Peer comparison

Anthem Biosciences operates within India's competitive CRDMO sector, alongside well-established players like Syngene International, Aragen Life Sciences, Sai Life Sciences, and Neuland Laboratories. These companies offer similar integrated services across the drug discovery, development, and manufacturing value chain. Anthem's move to bolster its subsidiary's equity through loan conversion is a strategic financial management tactic common among growing companies in this capital-intensive industry.

Context metrics (time-bound)

• As of February 23, 2026, the outstanding loan amount from Anthem Biosciences to Neoanthem Lifesciences was ₹439.41 Crores.

What to track next

• Investors will monitor for the completion of required approvals for the ₹275 crore loan-to-equity conversion.
• The company's ability to maintain robust corporate governance practices, especially following recent insider trading code violation disclosures.
• The future funding requirements and operational performance of Neoanthem Lifesciences.
• Any further strategic capital allocation or restructuring initiatives by Anthem Biosciences to support its growth trajectory.